US EditionShingles Vaccine Linked to Reduced Risks of Stroke, Myocardial Infarction, and Herpes Zoster Ophthalmicus
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Shingles Vaccine Linked to Reduced Risks of Stroke, Myocardial Infarction, and Herpes Zoster Ophthalmicus
The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.
Dynavax’s shingles vaccine shows promise in trial against GSK's Shingrix
Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against GSK's ShingrixThe post Dynavax’s shingles vaccine shows promise in trial against GSK’s Shingrix appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
